Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Wang, Hui ^a   Zhou, Jia ^a   Liu, Qiong Zhen ^b   Wang, Lu Lu ^a   Shang, Jing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NORTHWEST INSTITUTE OF PLATEAU BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; SEROTONIN; SIMVASTATIN; TRYPTOPHAN;

ANIMAL; ANIMAL BEHAVIOR; BLOOD; DEPRESSION; DRUG EFFECT; GLUCOSE TOLERANCE TEST; HIPPOCAMPUS; IMMOBILIZATION; LIPID DIET; MALE; MENTAL STRESS; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SWIMMING;

ANIMALS; BEHAVIOR, ANIMAL; BEZAFIBRATE; DEPRESSION; DIET, HIGH-FAT; GLUCOSE TOLERANCE TEST; HINDLIMB SUSPENSION; HIPPOCAMPUS; MALE; MICE; SEROTONIN; SIGNAL TRANSDUCTION; SIMVASTATIN; STRESS, PSYCHOLOGICAL; SWIMMING; TRYPTOPHAN;

EID: 85019905057     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-02576-5     Document Type: Article

References (59)

1. Ng, M., Fleming, T. & Robinson, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766-781 (2014).
2. Knol, M. J., Heerdink, E. R. & Egberts, A. C. et al. Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom Med 69, 300-305 (2007).
3. Detka, J., Kurek, A. & Basta-Kaim, A. et al. Neuroendocrine link between stress, depression and diabetes. Pharmacological Reports Pr. 65, 1591-1600 (2013).
4. Sharma, S. & Fulton, S. Diet-induced obesity promotes depressive-like behaviour that is associated with neural adaptations in brain reward circuitry. Int J Obes (Lond) 37, 382-9 (2013).
5. André, C., Dinel, A. L. & Ferreira, G. et al. Diet-induced obesity progressively alters cognition, anxiety-like behavior and lipopolysaccharide-induced depressive-like behavior: Focus on brain indoleamine 2, 3-dioxygenase activation. Brain Behav Immun 41, 10-21 (2014).
6. Boitard, C., Cavaroc, A. & Sauvant, J. et al. Impairment of hippocampal-dependent memory induced byjuvenile high-fat diet intake is associated with enhanced hippocampal inflammation in rats. Brain Behav Immun 40, 9-17 (2014).
7. Stranahan, A. M., Norman, E. D. & Lee, K. et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-Aged rats. Hippocampus 18, 1085-1088 (2008).
8. Citraro, R., Chimirri, S. & Aiello, R. et al. Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 55, 1284-1291 (2014).
9. Parsaik, A. K., Singh, B. & Hassan, M. M. et al. Statins use and risk of depression: A systematic review and meta-Analysis. J Affective Disorders 160, 62-67 (2014).
10. Lee, C. Y. Chronic restraint stress induces intestinal inflammation and alters the expression of hexose and lipid transporters. Clin ExpPharmacol Physiol 40, 385-91 (2013).
11. Kellett, G. L. Stress and intestinal sugar absorption. Am J PhysiolRegulIntegr Comp Physiol 292, R860-1 (2007).
12. Terasawa, T., Aso, Y. & Omori, K. et al. Bezafibrate, a peroxisome proliferator-Activated receptor α agonist, decreases circulating CD14+ CD16+, monocytes in patients with type 2 diabetes. Transl Res 165, 336-45 (2015).
13. Heneka, M. T., Sastre, M. & Dumitrescu-Ozimek, L. et al. Acute treatment with the PPAR gamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453 (2005).
14. Jiang, Q., Heneka, M. & Landreth, G. E. The role of peroxisome proliferator-Activated receptor-gamma (PPAR gamma) in Alzheimer's disease: Therapeutic implications. CNS Drugs 22, 1-14 (2008).
15. Nicolakakis, N., Aboulkassim, T. & Ongali, B. et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-Activated receptor gamma agonist. J Neurosci 28, 9287-9296 (2008).
16. Nicolakakis, N. & Hamel, E. The nuclear receptor PPAR gamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci 2, 1-10 (2010).
17. Ulusoy, G. K. et al. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Res Bull 85, 380-384 (2011).
18. Kiaei, M., Kipiani, K., Chen, J., Calingasan, N. Y. & Beal, M. F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191, 331-336 (2005).
19. Schutz, B., Reimann, J. & Dumitrescu-Ozimek, L. et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxidedismutase-G93A transgenic mice. J Neurosci 25, 7805-7812 (2005).
20. Kalonia, H., Kumar, P. & Kumar, A. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: Possible role of peroxisome proliferator activated receptor-I(PPARI) in Huntington's disease. Pharmacol Biochem Be 96, 115-124 (2010).
21. Quintanilla, R. A., Jin, Y. N., Fuenzalida, K., Bronfman, M. & Johnson, G. V. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-Activated receptor-gamma (PPAR gamma) in the pathogenesis of Huntington disease. J Biol Chem 283, 25628-25637 (2008).
22. Chen, X. R. et al. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 24, 1119-1131 (2007).
23. Dumont, M., Stack, C. & Elipenahli, C. et al. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet 21, 5091-5105 (2012).
24. Kaczmarczyk, M. M., Machaj, A. S. & Chiu, G. S. et al. Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice. Psychoneuroendocrino 38, 1553-1564 (2013).
25. Ai, Y., Mao, M. & Murao, S. et al. Effects of L-Theanine or caffeine intake on changes in blood pressure under physical and psychological stresses. J. Physiol. Anthropol 31, 621-646 (2012).
26. Harsha, S. N. & Anilakumar, K. R. Anxiolytic property of hydro-Alcohol extract of Lactuca sativa and its effect on behavioral activities of mice. J Biomed Res 27, 37-42 (2013).
27. Kurhe, Y., Radhakrishnan, M. & Gupta, D. Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. Metab Brain Dis 29, 701-710 (2014).
28. Collins, S. & Surwit, R. S. The beta-Adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog Horm Res 56, 309-28 (2001).
29. Surwit, R. S., Kuhn, C. M. & Cochrane, C. et al. Diet-induced type II diabetes in C57BL/6 mice. Diabetes 37, 1163-1167 (1988).
30. Winzell, M. S. & Bo, A. The High-Fat Diet-Fed Mouse: A Model for Studying Mechanisms and Treatment of Impaired Glucose Tolerance and Type 2 Diabetes. Diabetes 53, S215-9 (2005).
31. Schreyer, S. A., Wilson, D. L. & LeBoeuf, R. C. C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis 136, 17-24 (1988).
32. Winzell, M. S. & Ahren, B. The high-fat diet-fed mouse: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53, S215-9 (2004).
33. Krishna, S., Lin, Z. & Cb, D. L. S. et al. Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake. Physiol Behav 83, 196-208 (2016).
34. Zemdegs, J., Quesseveur, G. & Jarriault, D. et al. High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice. Brit J Pharmacol 173, 2095-2110 (2016).
35. Can, Ö. D., Uluplnar, E. & Özkay, Ü. D. et al. The effect of simvastatin treatment on behavioral parameters, cognitive performance, and hippocampal morphology in rats fed a standard or a high-fat diet. Behav Pharmacol 23, 582-592 (2012).
36. Liu., L., Aa, J. & Wang, G. et al. Differences in metabolite profile between blood plasma and serum. Anal Biochem 406, 105-112 (2010).
37. Chang., Y. H., Kim, J. Y. & Paik, J. K. et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol 76, 674-682 (2012).
38. Byeon, S. K., Jin, Y. K. & Ju, Y. L. et al. Top-down and bottom-up lipidomic analysis of rabbit lipoproteins under different metabolic conditions using flow field-flow fractionation, nanoflow liquid chromatography and mass spectrometry. J Chromatogr A 1405, 140-148 (2015).
39. Bossong, M. G., Jansma, J. M. & Bhattacharyya, S. et al. Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or â9-Tetrahydrocannabinol (THC). Prog Neuro-psycho Ph 52, 53-69 (2014).
40. Zhang, M., Martin, B. R. & Adler, M. W. et al. Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and Stroke. J Neuroimmune Pharm 4, 249-259 (2009).
41. Benito, C., Núñez, E. & Pazos, M. R. et al. The Endocannabinoid System and Alzheimer's disease. Mol Neurobiol 36, 75-81 (2007).
42. Richardson, D., Ortori, C. A. & Chapman, V. et al. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-Tandem electrospray ionization mass spectrometry. Anal Biochem 360, 216-26 (2007).
43. Esposito, E., Impellizzeri, D. & Mazzon, E. et al. Neuroprotective Activities of Palmitoyleth-anolamide in an Animal Model of Parkinson's disease. Plos One 7, e41880 (2012).
44. Re, G., Barbero, R. & Miolo, A. et al. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Vet J 173, 21-30 (2007).
45. Garg, P., Duncan, R. S. & Kaja, S. et al. Intracellular mechanisms of N-Acylethanolamine-mediated neuroprotection in a rat model of stroke. Neuroscience 166, 252-62 (2010).
46. Ishida, T., Nishiumi, S. & Tanahashi, T. et al. Linoleoyl ethanolamide reduces lipopolysaccharide-induced inflammation in macrophages and ameliorates 2,4-dinitrofluorobenzene-induced contact dermatitis in mice. Eur J Pharmacol 699, 6-13 (2013).
47. Palandra, J., Prusakiewicz, J. & Ozer, J. S. et al. Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization. J Chromatogr B 877, 2052-2060 (2009).
48. O'Mahony, S. M., Clarke, G. & Borre, Y. E. et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 277, 32-48 (2015).
49. Blier, P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiat 74, S19-24 (2013).
50. Li, J., Tang, G. & Cheng, K. et al. Peripheral blood mononuclear cell-based metabolomic profiling of a chronic unpredictable mild stress rat model of depression. Mol Biosyst 10, 2994-3001 (2014).
51. Zheng, X., Kang, A. & Dai, C. et al. Quantitative analysis of neurochemical panel in rat brain and plasma by liquid chromatography-Tandem mass spectrometry. Anal Chem 84, 10044-10051 (2012).
52. Kim, H. J., Kim, J. H. & Noh, S. et al. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J Proteome Res 10, 722-731 (2011).
53. Kim, M., Bae, S. & Lim, K. M. Impact of High Fat Diet-induced Obesity on the Plasma Levels of Monoamine Neurotransmitters in C57BL/6 Mice. Biomol Ther 21, 476-80 (2013).
54. Romani, L., Fallarino, F., De & Luca, A. et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451, 211-215 (2008).
55. Stone, T. W., Forrest, C. M. & Darlington, L. G. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS. J. 279, 1386-1397 (2012).
56. Ruddick, J. P., Evans, A. K. & Nutt, D. J. et al. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 8, 1-27 (2006).
57. Le Floc'h, N., Otten, W. & Merlot, E. Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids 41, 1195-205 (2011).
58. Raison, C. L., Dantzer, R. & Kelley, K. W. et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-Alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15, 393-403 (2010).
59. Guilloux, J. P., Seney, M. & Edgar, N. et al. Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex. J Neurosci Meth 197, 21-31 (2011).